Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlatrelvir
- Development stage
- Phase 3
- Lead developer
- Raynovent Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Anlatrelvir (formerly ZSP1273) is a potent, highly selective, orally administered small molecule inhibitor of the influenza A virus polymerase basic protein 2 (PB2) subunit. Developed by Raynovent Biotechnology, it targets the cap-binding domain of PB2, thereby inhibiting the "cap-snatching" process required for viral mRNA synthesis and effectively halting viral replication. In clinical trials, anlatrelvir demonstrated superior efficacy in reducing viral load and symptom duration compared to oseltamivir. It was approved by the China National Medical Products Administration (NMPA) in early 2024 for the treatment of adult patients with uncomplicated influenza A and is currently being investigated in Phase 3 trials for pediatric populations.
- Brand names
- Anruiwei安睿威
- Other names
- 昂拉地韦昂拉地韦片昂拉地韦颗粒Anlatrelvir tabletsAnlatrelvir granules
02
Targets
PB2 (Influenza PB2)
Beyond the preview
Go deeper on anlatrelvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlatrelvir.